1-111982463-G-A

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_001378969.1(KCND3):​c.264C>T​(p.Pro88Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.106 in 1,612,354 control chromosomes in the GnomAD database, including 10,185 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.082 ( 618 hom., cov: 32)
Exomes 𝑓: 0.11 ( 9567 hom. )

Consequence

KCND3
NM_001378969.1 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: -3.11

Publications

10 publications found
Variant links:
Genes affected
KCND3 (HGNC:6239): (potassium voltage-gated channel subfamily D member 3) Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shal-related subfamily, members of which form voltage-activated A-type potassium ion channels and are prominent in the repolarization phase of the action potential. This member includes two isoforms with different sizes, which are encoded by alternatively spliced transcript variants of this gene. [provided by RefSeq, Jul 2008]
KCND3 Gene-Disease associations (from GenCC):
  • neurodevelopmental disorder
    Inheritance: AD Classification: STRONG Submitted by: G2P
  • spinocerebellar ataxia type 19/22
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet, Ambry Genetics
  • Brugada syndrome 9
    Inheritance: AD Classification: LIMITED Submitted by: Genomics England PanelApp
  • Brugada syndrome 1
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 1-111982463-G-A is Benign according to our data. Variant chr1-111982463-G-A is described in ClinVar as Benign. ClinVar VariationId is 129314.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-3.11 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.118 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
KCND3NM_001378969.1 linkc.264C>T p.Pro88Pro synonymous_variant Exon 2 of 8 ENST00000302127.5 NP_001365898.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
KCND3ENST00000302127.5 linkc.264C>T p.Pro88Pro synonymous_variant Exon 2 of 8 5 NM_001378969.1 ENSP00000306923.4 Q9UK17-1

Frequencies

GnomAD3 genomes
AF:
0.0823
AC:
12522
AN:
152126
Hom.:
618
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0460
Gnomad AMI
AF:
0.0921
Gnomad AMR
AF:
0.0630
Gnomad ASJ
AF:
0.0734
Gnomad EAS
AF:
0.00116
Gnomad SAS
AF:
0.0561
Gnomad FIN
AF:
0.0646
Gnomad MID
AF:
0.0886
Gnomad NFE
AF:
0.120
Gnomad OTH
AF:
0.0727
GnomAD2 exomes
AF:
0.0842
AC:
21137
AN:
251016
AF XY:
0.0866
show subpopulations
Gnomad AFR exome
AF:
0.0463
Gnomad AMR exome
AF:
0.0415
Gnomad ASJ exome
AF:
0.0738
Gnomad EAS exome
AF:
0.000870
Gnomad FIN exome
AF:
0.0660
Gnomad NFE exome
AF:
0.126
Gnomad OTH exome
AF:
0.0871
GnomAD4 exome
AF:
0.109
AC:
159107
AN:
1460110
Hom.:
9567
Cov.:
33
AF XY:
0.108
AC XY:
78351
AN XY:
725930
show subpopulations
African (AFR)
AF:
0.0423
AC:
1413
AN:
33438
American (AMR)
AF:
0.0442
AC:
1974
AN:
44700
Ashkenazi Jewish (ASJ)
AF:
0.0762
AC:
1987
AN:
26088
East Asian (EAS)
AF:
0.000883
AC:
35
AN:
39636
South Asian (SAS)
AF:
0.0645
AC:
5557
AN:
86214
European-Finnish (FIN)
AF:
0.0698
AC:
3729
AN:
53390
Middle Eastern (MID)
AF:
0.0746
AC:
430
AN:
5766
European-Non Finnish (NFE)
AF:
0.125
AC:
138278
AN:
1110584
Other (OTH)
AF:
0.0946
AC:
5704
AN:
60294
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.485
Heterozygous variant carriers
0
9532
19064
28596
38128
47660
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
4832
9664
14496
19328
24160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0822
AC:
12522
AN:
152244
Hom.:
618
Cov.:
32
AF XY:
0.0792
AC XY:
5891
AN XY:
74416
show subpopulations
African (AFR)
AF:
0.0459
AC:
1906
AN:
41562
American (AMR)
AF:
0.0629
AC:
962
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.0734
AC:
255
AN:
3472
East Asian (EAS)
AF:
0.00116
AC:
6
AN:
5166
South Asian (SAS)
AF:
0.0557
AC:
268
AN:
4812
European-Finnish (FIN)
AF:
0.0646
AC:
685
AN:
10608
Middle Eastern (MID)
AF:
0.0918
AC:
27
AN:
294
European-Non Finnish (NFE)
AF:
0.120
AC:
8176
AN:
68006
Other (OTH)
AF:
0.0724
AC:
153
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
603
1205
1808
2410
3013
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
152
304
456
608
760
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.103
Hom.:
792
Bravo
AF:
0.0813
Asia WGS
AF:
0.0260
AC:
91
AN:
3478
EpiCase
AF:
0.115
EpiControl
AF:
0.123

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:6
Sep 28, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 23, 2016
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

Apr 05, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Cardiovascular phenotype Benign:1
Jun 18, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Spinocerebellar ataxia type 19/22 Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
1.9
DANN
Benign
0.85
PhyloP100
-3.1
PromoterAI
0.0087
Neutral
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17221819; hg19: chr1-112525085; COSMIC: COSV56190733; API